[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643631":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":11,"centralContacts":38,"locations":11,"responsibleParty":44,"collaborators":11,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":11,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":11,"enrollmentInfo":55,"targetDuration":11,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":11,"overallStatus":64,"whyStopped":11,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":11},{"fullName":5,"class":6},"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","INDUSTRY",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"SYH2068 Dose 1","EXPERIMENTAL",null,[13],"Drug: SYH2068 Dose 1",{"label":15,"type":10,"description":11,"interventionNames":16},"SYH2068 Dose 2",[17],"Drug: SYH2068 Dose 2",{"label":19,"type":10,"description":11,"interventionNames":20},"SYH2068 Dose 3",[21],"Drug: SYH2068 Dose 3",{"label":23,"type":24,"description":11,"interventionNames":25},"Placebo","PLACEBO_COMPARATOR",[26],"Drug: Placebo",[28,32,34,36],{"type":29,"name":9,"description":30,"armGroupLabels":31,"otherNames":11},"DRUG","Administered by subcutaneous injection.",[9],{"type":29,"name":15,"description":30,"armGroupLabels":33,"otherNames":11},[15],{"type":29,"name":19,"description":30,"armGroupLabels":35,"otherNames":11},[19],{"type":29,"name":23,"description":30,"armGroupLabels":37,"otherNames":11},[23],[39],{"name":40,"role":41,"phone":42,"phoneExt":11,"email":43},"Clinical Trials Information Group officer","CONTACT","0311-69085587","ctr-contact@cspc.cn",{"type":45,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100643631","phase-2-a-phase-ii-clinical-study-of-syh2068-injection-in-adults-with-elevated-lipoproteina-100643631",false,"NCT07640217","A Phase II Clinical Study of SYH2068 Injection in Adults With Elevated Lipoprotein(a)","A Phase II Randomized, Double-Blind, Parallel-group, Placebo-Controlled Trial of SYH2068 Injection in Adults With Elevated Lipoprotein(a)","Inclusion Criteria:\n\n1. Male or female participants ≥18 years of age;\n2. Elevated Lp(a);\n3. Participants who have used lipid-lowering drugs continue to use a stable dose, and those who have not used do not start new lipid-lowering drugs;\n4. Presence of ASCVD or ASCVD risk stratification assessed as moderate or high risk;\n5. Participants are able to understand and cooperate to complete this study, voluntarily participate in this study, and sign the ICF.\n\nExclusion Criteria:\n\n1. Diseases that significantly affect Lp(a) during screening period,\n2. Major or unstable cardiovascular events occurring from 3 months before signing the ICF to randomization;\n3. Undergoing or expected to undergo peripheral arterial, coronary, or cerebrovascular revascularization surgery or other major surgery within 3 months prior to signing the ICF until randomization or during the study period;\n4. NYHA class III-IV at the time of signing the ICF or LVEF \\\u003C40% during the screening period;\n5. Type 1 diabetes or hereditary hemorrhagic disorder at screening;\n6. History of malignant tumor or suspected malignancy within 5 years prior to screening;\n7. Use of drugs affecting Lp(a) within the specified period before screening or expected to use during the study period;\n8. Allergy to oligonucleotide drugs;\n9. Received any other clinical study treatment within 3 months prior to screening or within 5 half-lives of the investigational drug;\n10. Female participants who are pregnant or breastfeeding at screening, or female \u002F male participants who plan to conceive during the study and within 1 year after the last dose.","ALL","18 Years",{"count":56,"type":57},120,"ESTIMATED","INTERVENTIONAL",[60],"PHASE2","The purpose of this study is to evaluate the efficacy and safety of SYH2068 injection in patients with elevated lipoprotein(a).",[63],"Adult Participants With Elevated Lipoprotein(a)","NOT_YET_RECRUITING","2026-06-05",{"date":67,"type":68},"2026-06-10","ACTUAL",{"date":70,"type":57},"2026-07-30",{"date":72,"type":57},"2028-09-30",{"name":5,"class":6}]